Stingray Therapeutics, Inc. — Form D/A
Stingray Therapeutics, Inc. of DALLAS, TX, a company, filed a Form D amendment with the SEC on 2021-05-26. The offering totals $3.0M, of which $1.5M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2021-05-26
- Form: D/A
- Accession: 0001759143-21-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $3.0M
- Amount sold: $1.5M
- Remaining: $1.5M
- Investors: 9
- Date of first sale: 2020-07-31
- Security types: debt
- Revenue range: Decline to Disclose
- SEC file number: 021-373125
Issuer
- Name: Stingray Therapeutics, Inc.
- CIK: 0001759143
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2018
- Address: HEALTH WILDCATTERS INCUBATOR, DALLAS, TX, 75247
- Phone: 317-517-9500
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| Scott Andrew Jordan | Director | Houston, TX |
| Scott Andrew Jordan | Executive Officer | Houston, TX |
| Scott Andrew Jordan | Promoter | Houston, TX |
| Jonathan P Northrup | Promoter | Gaithersburg, MD |
| Sunil P Sharma | Promoter | Dallas, TX |
| Sunil P Sharma | Director | Dallas, TX |
| Sunil P Sharma | Executive Officer | Dallas, TX |
| Uma P Bhatt | Director | Dallas, TX |
| Uma P Bhatt | Executive Officer | Dallas, TX |
| Jonathan P Northrup | Director | Gaithersburg, MD |
| Jonathan P Northrup | Executive Officer | Gaithersburg, MD |
Other filings by this issuer (6)
More